[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University Hospital Hradec Kralove\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":272},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,51,80,108,129,151,174,199,222,250],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100642717","prophylactic-use-of-cinpwt-in-gynecologic-laparotomy-100642717",false,"NCT07645547","Prophylactic Use of ciNPWT in Gynecologic Laparotomy","Implementation of Prophylactic Negative Pressure Wound Therapy (ciNPWT) in High-Risk Patients in Gynecologic Oncology: A Prospective Feasibility Study and Nested Qualitative Analysis","Inclusion Criteria:\n\n* Adult female patients scheduled for planned abdominal surgery for gynecologic or gynecologic-oncologic indications.\n\nIdentification as \"high-risk\" for wound healing complications based on a clinical risk screening at admission.\n\nSigned informed consent.\n\nExclusion Criteria:\n\n* Failure to provide informed consent.","FEMALE","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a prospective, open-label, non-randomized interventional feasibility study with a nested qualitative analysis. The study exploratively verifies the feasibility of targeted prophylactic closed incision negative pressure wound therapy (ciNPWT) in clinical practice for patients with a high predicted risk of wound healing complications and compares the 30-day incidence of postoperative complications with standard dressing.\n\nParticipants will:\n\n* Get ciNPWT or standard dressing after planned laparotomy\n* Answer the questionairs about qualite of life\n* Will visit the clinic 30 days after surgery to see the final result",[26,27,28,29,30],"Surgical Site Infection (SSI)","Wound Healing Complication","Seroma","Hematoma","Dehiscence",[32,33,34,35,36,37,38],"ciNPWT","laparotomy","surgical site infection","SSI","feasibility","PROMs","ASEPSIS","NOT_YET_RECRUITING","2026-06-11",{"date":42,"type":43},"2026-06-12","ACTUAL",{"date":45,"type":20},"2026-07",{"date":47,"type":20},"2028-12",{"name":49,"class":50},"University Hospital Hradec Kralove","OTHER",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100621252","preoperative-risk-stratification-in-endometrial-cancer-for-tailoring-lymph-node-staging-100621252","NCT07368205","Preoperative Risk Stratification in Endometrial Cancer for Tailoring Lymph Node Staging","Preoperative Risk Stratification in Endometrial Cancer Using Expert Ultrasound and Molecular Classification for Tailoring Lymph Node Staging: Multicentric Prospective Observational Study","PRSTEC_multipr","Inclusion Criteria:\n\n* Women ≥18 years with newly diagnosed endometrial cancer (any histology)\n* Undergoing primary surgical management\n* Preoperative expert ultrasound, CT scan (could be waived in low risk cases)\n* Preoperatively early-stage (stage I-II) of EC\n* SLN mapping attempted intraoperatively\n* FFPE tumor tissue available for molecular and IHC testing from biopsy\n* Signed informed consent with the participation in the study\n\nExclusion Criteria:\n\n* Neoadjuvant treatment\n* Recurrent or metastatic disease at diagnosis\n* Inadequate imaging or tissue samples\n* Cancer synchronous duplicity\n* Prior oncological treatment within the last five years",{"count":60,"type":20},350,"OBSERVATIONAL","The goal of this observational study is to evaluaty the accuracy of current risk stratification of patients with endometrial cancer and to redefine lymph node staging recommendations based on real-world clinical data. The main question it aims to answer is:\n\nIs there any group of patients who doesn't need lymph node staging for proper indication of adjuvant treatment? Participants are note taking any intervention. They are treated according to current standard of care and followed 3-years after primary surgery.",[64],"Endometrial Cancer",[66,67,68,69],"endometrial cancer","molecular classification","expert ultrasonography","lymph node staging","RECRUITING","2026-05-18",{"date":73,"type":43},"2026-05-22",{"date":75,"type":43},"2026-02-15",{"date":77,"type":20},"2031-02",{"name":49,"class":50},1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":88,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":79},"100624901","phase-2-modulation-of-cerebral-ischemia-by-albumin-100624901","NCT07415655","Modulation of Cerebral Ischemia by Albumin","Modulation of the Extent of Ischemic Brain Damage by Protecting the Endothelial Glycocalyx With Low-Dose Albumin Administration","MOZEG","Inclusion Criteria:\n\n* ischemic stroke in the anterior circulation with or without thrombolysis administration\n* vasographic intervention indication\n\nExclusion Criteria:\n\n* pregnancy, breastfeeding\n* known albumin hypersensitivity\n* hypervolemia, hyperhydration\n* hypernatremia\n* another study participation","ALL",{"count":90,"type":20},100,[92],"PHASE2","A single-center, open-label, randomized, placebo-controlled, prospective phase II clinical trial to investigate the efficacy of low-dose albumin in patients with ischemic stroke with an indication for vasographic intervention. The clinical trial consists of the following phases: Screening, randomization, treatment phase - administration of albumin\u002Fplacebo and vasographic intervention (with the duration of all these 3 phases in the order of hours) and a follow-up phase, which takes place first in the intensive care unit (ICU) and then in a standard ward and lasts 90 (±7) days. The clinical trial ends with the End of Study\u002FDay 90 visit. The total maximum duration of patient participation in the clinical trial is therefore 97 days, including Follow-up.\n\nIschemic stroke is caused by local perfusion impairment due to thromboembolism or thrombosis at the site of perfusion impairment. The damaged brain area is projected into the patient's neurological clinical picture. The primary stroke cannot be influenced by therapeutic procedures, however, the area of the so-called penumbra (the surroundings of the ischemic lesion, where vasoreactivity is impaired and the blood-brain barrier is more or less damaged) can be, which is the main goal of therapy, as well as improving the neurological clinical outcome of patients as much as possible (thrombolysis, neuroangiointervention). Research over the past 20 years has highlighted the importance of the endothelial glycocalyx (EG) and has proposed a number of concepts and substances with a protective and reparative effect.\n\nAlbumin has come to the forefront of interest. The study assumes a benefit for patients in the form of non-circulatory effects of administered albumin: improvement of EG condition in the penumbra area of the ischemic focus, improvement of microrheology, and antioxidant protection. Albumin therapy has been used for 80 years and is generally well tolerated. Allergy to albumin is rare, as it is a protein of the body's own from healthy donors. The concomitantly used medicinal products are highly purified. The selected dosage should not endanger the patient in any way in terms of circulatory overload, pulmonary edema, and, we assume, also in terms of bleeding into the ischemic focus of the brain.\n\nStudy drug: albumin. Any albumin available on the market in the dose and strength specified in the protocol can be used. The reference SmPC is Alburex (manufacturer CSL Behring). Placebo: Fresenius Kabi 0.9% saline solution.\n\nIt is planned to enroll 100 patients.",[95],"Ischemic Stroke",[97,98,99],"endothelial glycocalyx","ischemic stroke","albumin","2026-04-30",{"date":102,"type":43},"2026-05-06",{"date":104,"type":43},"2026-02-03",{"date":106,"type":20},"2028-02-01",{"name":49,"class":50},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":88,"minAge":17,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":79},"100486057","endothelial-glycocalyx-damage-in-brain-death-organ-donors-100486057","NCT05609123","Endothelial Glycocalyx Damage in Brain Death Organ Donors","Endothelial Glycocalyx Status and Damage in Brain Death Organ Donors","Inclusion Criteria:\n\n* patients in critical condition declared as brain dead by clinical examination\n\nExclusion Criteria:\n\n* N\u002FA",{"count":90,"type":20},"The study aims the assessment of endothelial glycocalyx (EG) degradation in deceased organ donors. There is a lack of organs for the transplantation program. By the description of the EG status, we can open room for organ optimization before transplantation and improve the organ function after transplantation in marginal donors.",[118,119,120],"Brain Damage Due to Hypoxia","Organ Donors","Organ Transplant Failure or Rejection","2026-04-27",{"date":123,"type":43},"2026-05-01",{"date":125,"type":43},"2022-01-01",{"date":127,"type":20},"2027-12-31",{"name":49,"class":50},{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":79},"100569081","ultrasound-guided-tru-cut-biopsy-in-patients-with-suspected-ovarian-cancer-adequacy-accuracy-safety-and-patient-assessment-100569081","NCT06689605","Ultrasound-guided Tru-cut Biopsy in Patients with Suspected Ovarian Cancer: Adequacy, Accuracy, Safety and Patient Assessment.","TRUCUTOC","Inclusion Criteria:\n\n* suspected advanced ovarian cancer\n* indication for tru-cut biopsy by multidisciplinary oncoboard\n\nExclusion Criteria:\n\n* patient deny to undergo tru-cut biopsy",{"count":19,"type":20},"The goal of this prospective observational study is to evaluate the role of ultrasound-guided tru-cut biopsy (in the hands of an expert certified sonographer within a gynecological center)in patients with suspected ovarian cancer.\n\nThe main questions it aims to answer are:\n\nIs the material from tru-cut biopsy adequate for histopathological and immunohistochemical examination? Is the material accurate in comparison with the final pathological specimen? What are the patient experience and complications after the procedure?\n\nParticipants who will undergo a standard tru-cut biopsy procedure will need to additionally answer the questionnaire.",[139],"Ovarian Cancer",[141,142,68],"ovarian cancer","tru-cut biopsy","2025-03-25",{"date":145,"type":43},"2025-03-26",{"date":147,"type":43},"2025-01-01",{"date":149,"type":20},"2026-12",{"name":49,"class":50},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":88,"minAge":17,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":79},"100485858","the-impact-of-intra-operative-fluid-infusion-rate-on-microcirculation-100485858","NCT05606536","The Impact of Intra-operative Fluid Infusion Rate on Microcirculation","The Impact of Intra-operative Fluid Infusion Rate on Hemodilution and Microcirculation Prospective Observational Pilot Study","Inclusion Criteria:\n\n* elective recumbent and laparoscopic surgery\n* informed consent\n\nExclusion Criteria:\n\n* blood loss over 250 ml\n* hemodynamic instability requiring noradrenaline infusion",{"count":159,"type":20},80,[23],"Intraoperative fluid therapy (IFT) is an integral part of anesthesia care during surgery. Its main indication is the optimization of oxygen supply to the tissues. For elective surgery that is not associated with higher blood loss and a long period of preoperative fasting, including fluids IFT is dosed to cover the basal daily need for fluids. However, it is not clear whether this fluid dose is optimal. Surgery is a stress factor that leads, among other things, to damage of the endothelial glycocalyx (EG). EG binds a significant amount of plasma, which is released during EG destruction and causes relative hemodilution.\n\nIsovolumic hemodilution is an established intraoperative procedure that serves to better control bleeding in procedures where bleeding is expected. However, partial hemodilution occurs even with standard IFT, and even when fluids are hardly given at all. Flow parameters in microcirculation have not yet been described depending on IFT conduction. The parameters of the microcirculation reflect its functioning, which will consequently affect the postoperative phase of the patient's moaning and clinical outcome.",[163,164,165],"Fluid Therapy","Microcirculation","Hemodilution","2025-03-24",{"date":168,"type":43},"2025-03-27",{"date":170,"type":43},"2022-10-01",{"date":172,"type":20},"2025-12-31",{"name":49,"class":50},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":88,"minAge":17,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":79},"100430633","dynamics-of-markers-of-infection-and-inflammation-in-hospitalized-coronavirus-disease-2019-covid-19-patients-100430633","NCT04887623","Dynamics of Markers of Infection and Inflammation in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients","Dynamics of Nucleocapsid Antigen Serum Levels and Other Markers of Infection and Inflammation in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients - a Pilot Study","Inclusion Criteria:\n\n* SARS CoV2 positive test within last 14 day\n* bilateral infiltrates on chest X.ray or CT\n* need for oxygen to keep pulse oximetry saturation above 92% or other respiratory support measures (HFNO, non-invasive ventilation or invasive ventilation)\n\nExclusion Criteria:\n\n* known history of intersticial lung disease\n* known history of congestive heart failure","90 Years",{"count":19,"type":20},"Patients requiring admission to the hospital due to a moderate and severe COVID-19 infection may differ in their ability to respond to viral infection and to eliminate viral load.\n\nSeveral comorbidities and interventions like antivirotic or antiinflammatory treatment may also modify expected patients response and decrease of viral load.\n\nIn this observational study, evolution of selected inflammatory markers, indicators of severity of infection and patient characteristics will be followed and recorded in hospitalized patients with COVID-19.",[185],"COVID-19 Respiratory Infection",[187,188,189,190],"Covid19","Interleukin 6","viremia","nucleocapsid antigen","2024-05-09",{"date":193,"type":43},"2024-05-10",{"date":195,"type":43},"2021-04-01",{"date":197,"type":20},"2026-08",{"name":49,"class":50},{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":88,"minAge":17,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":21,"phases":208,"briefSummary":209,"conditions":210,"keywords":212,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":79},"100371317","haemodynamical-optimization-during-brain-surgery-100371317","NCT04114799","Haemodynamical Optimization During Brain Surgery","A Comparison of Perioperative Fluid Management Using Invasive Haemodynamical Measurement of Fluid Responsiveness (Aisys GE) and Non-invasive Measurement of Haemodynamics (ClearSight System, Edwards) During Brain Surgery","Inclusion Criteria:\n\n* Glasgow Coma scale 15\n* ASA Physical Status Classification System I-III\n* planed surgery for brain tumor to 5 hours\n* postoperative awakening\n* sinus rhythm\n\nExclusion Criteria:\n\n* NYHA III, IV\n* BMI over 40 in females and over 35 in men\n* awake operation\n* postoperative artificial ventilation",{"count":207,"type":20},50,[23],"The decision to give fluids perioperatively could be based on methods used to identify preload responsiveness, either invasive or noninvasive estimates of stroke volume variation during mechanical ventilation. This study compares fluid management using invasive measurement SPV\u002FPPV (Aisys GE) and noninvasive haemodynamic measurement (ClarSight, Edwards).",[211],"Brain Edema",[213,214,215],"fluid responsiveness","haemodynamical monitoring","ClearSight",{"date":193,"type":43},{"date":218,"type":43},"2019-04-01",{"date":220,"type":20},"2026-11-30",{"name":49,"class":50},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":88,"minAge":17,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":21,"phases":232,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":79},"100335224","the-influence-of-prone-position-for-spinal-surgery-on-visual-acuity-100335224","NCT03644641","The Influence of Prone Position for Spinal Surgery on Visual Acuity","The Influence of Prone Position for Spinal Surgery on Visual Acuity, a Comparison of Volatile Anesthesia With Desflurane to Total Intravenous Anesthesia With Propofol","Inclusion Criteria:\n\n* Glasgow Coma scale 15\n* American Society of Anesthesiologists (ASA) Physical Status Classification System I-III\n* spinal surgery in duration less than 3 hours\n* sinus rhythm\n\nExclusion Criteria:\n\n* postoperative artificial ventilation\n* serious neurological disease\n* lung disease with hypercapnia\n* propofol allergy","65 Years",{"count":231,"type":20},60,[23],"This study investigated the effect of desflurane and propofol anesthesia on visual acuity in patients in prone position for spinal surgery. Many trials have investigated the effects of different anesthetic agents on intraocular pressure, propofol may reduce intraocular pressure more than other intravenous anesthetics.",[235],"Vision; Disorder, Loss",[237,238,239,240,241,242,243],"Desflurane","Near-infrared spectroscopy","Propofol","Spinal surgery","Prone position","Visual acuity","Visual loss",{"date":193,"type":43},{"date":246,"type":20},"2025-11-28",{"date":248,"type":20},"2029-12-30",{"name":49,"class":50},{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":255,"acronym":4,"eligibilityCriteria":256,"healthyVolunteers":11,"sex":88,"minAge":17,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":21,"phases":258,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":79},"100322308","manual-versus-targer-controll-infusion-in-reduction-of-awareness-and-dreaming-100322308","NCT03476213","Manual Versus Targer-controll Infusion in Reduction of Awareness and Dreaming","Reduction of Awareness and Dreaming During Neurosurgical Procedures Using Target- Controlled Infusion, Comparison With Manual Total Intravenous Anesthesia TIVA.","Inclusion Criteria:\n\n* Glasgow Coma scale 15\n* ASA Physical Status Classification System I - III\n* planed surgery for brain tumor to 5 hours\n* postoperative awakening\n\nExclusion Criteria:\n\n* NYHA III, IV\n* abuse of stimulating drugs, grass, alcohol dependence\n* BMI over 40 in females and over 35 in men\n* propofol alergie\n* awake operations\n* postoperative arteficial ventilation",{"count":159,"type":20},[23],"This study compares manual total intravenous anesthesia (TIVA) and target-controll infusion (TCI) in reduction of awareness and dreaming, and the haemodynamical stability during operation. Half of patients will be anesthetized using manual TIVA and other half using TCI.",[261],"Anesthesia Awareness",[261,263,264,265],"Dreaming in anesthesia","Total intravenous anesthesia","Target-controll infusion",{"date":193,"type":43},{"date":268,"type":43},"2018-03-16",{"date":270,"type":20},"2027-06-30",{"name":49,"class":50},""]